Navigation Links
Chimerix to Present at Upcoming Investor Conferences
Date:6/2/2010

RESEARCH TRIANGLE PARK, N.C., June 2 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present at two upcoming investor conferences:  the 9th Annual Needham Healthcare Conference, 9:00 AM ET, June 9, 2010, and the Jefferies 2010 Global Life Sciences Conference, 12:45 PM ET, June 11, 2010. The conferences are being held in New York City.

Mr. Moch will provide a corporate overview, including an update on the company's clinical-stage candidates, CMX001 and CMX157.  CMX001 is an orally-available, broad-spectrum antiviral being developed for the treatment of dsDNA viral infections in immunocompromised patients.  The compound is in Phase 1 and 2 clinical trials for the treatment of cytomegalovirus and BK virus.  CMX157, a novel lipid conjugate of the drug tenofovir, was created to improve upon the efficacy and safety of the prodrug Viread®, the leading nucleoside reverse transcriptase inhibitor (NRTI) used in the treatment of HIV patients.  CMX157, which is in Phase 1 clinical trials, is being developed for its potential to reduce systemic toxicity and enable the development of one-pill once-a-day fixed dose anti-HIV combinations.

About Chimerix

Chimerix is developing antiviral therapeutics to treat life-threatening diseases.  Led by a world-class antiviral drug development team, Chimerix is advancing programs to address cytomegalovirus (CMV), BK virus, adenovirus, smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza.  The company's lead compound, CMX001, is in Phase 1 and Phase 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections among immunocompromised patients.  CMX001 is also being developed as a biodefense countermeasure in the event of a smallpox release.  Chimerix has advanced a second antiviral compound, CMX157, into Phase 1 clinical studies.  CMX157 is being developed as a potential once-weekly nucleoside analogue against HIV infections.  Building on the company's extensive chemical library, Chimerix is also pursuing translational medicine efforts to address malaria, dengue fever and other public health needs.  Chimerix has received financing from leading venture capital firms, including Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Company and Frazier Healthcare Ventures, as well as significant funding from the National Institute of Allergy and Infectious Diseases.  Additional information about Chimerix and its antiviral drug development programs may be found online at http://www.chimerix.com.


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Chimerix Initiates Phase 1 Study of CMX157
2. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
3. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
4. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
5. Chimerix Joins International Network of Organizations to Cure Malaria
6. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
7. Merial to Screen Chimerix Chemical Library for Animal Health Drug Leads
8. Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer
9. NeoGenomics to Present at Noble Financials 6th Annual Equity Conference on Monday, June 7th
10. China-Biotics to Present at Bank of America Merrill Lynch Healthcare Event on June 22
11. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... operations for Amgen, will join the faculty of the University of North ... adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS ... the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, ... proud to add Target to its list of well-respected retailers. This list includes ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
Breaking Biology Technology:
(Date:6/9/2016)... , June 9, 2016 ... deploy Teleste,s video security solution to ensure the safety of ... during the major tournament Teleste, an ... systems and services, announced today that its video security solution ... to back up public safety across the country. The ...
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
Breaking Biology News(10 mins):